Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

Taking a GLP-1 receptor agonist prior to bariatric surgery may not boost long-term weight loss and metabolic benefits, a ...

A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide - also known as Ozempic - in suppressing appetite and reducing body weight.

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before ...

Patients using popular weight loss medications, such as Ozempic and Wegovy, are being urged to undergo eye examinations due ...

Researchers at Stanford Medicine have discovered a naturally occurring molecule that mimics the effects of semaglutide ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

By now we have all heard about Semaglutide (Ozempic) and Tirzepatide (Mounjaro).  Whether you have used it yourself or know of someone who has, we know how effective ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

Novo Nordisk A/S can intervene in a lawsuit between the FDA and drug compounders over whether its blockbuster drugs Wegovy ...